• Neurocrine Biosciences released survey findings showing fewer work and school disruptions among adults with tardive dyskinesia taking Ingrezza.
• A separate post-hoc analysis of the Phase 4 KINECT-PRO study showed patient-reported improvements in physical functioning and socio-emotional well-being with Ingrezza.
• The findings will be presented at the Neuroscience Education Institute Fall Congress, Nov. 5-8, 2026, in Colorado Springs, Colorado.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611050830PR_NEWS_USPR_____LA89159) on November 05, 2026, and is solely responsible for the information contained therein.